- Home
- KTB vs AKRO Comparison
KTB vs AKRO Comparison
Compare KTB & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTB
- AKRO
- Stock Information
- Founded
- KTB 2018
- AKRO 2017
- Country
- KTB United States
- AKRO United States
- Employees
- KTB N/A
- AKRO N/A
- Industry
- KTB Apparel
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- KTB Consumer Discretionary
- AKRO Health Care
- Exchange
- KTB Nasdaq
- AKRO Nasdaq
- Market Cap
- KTB 4.0B
- AKRO 4.5B
- IPO Year
- KTB N/A
- AKRO 2019
- Fundamental
- Price
- KTB $70.01
- AKRO $54.39
- Analyst Decision
- KTB Strong Buy
- AKRO Buy
- Analyst Count
- KTB 8
- AKRO 10
- Target Price
- KTB $96.38
- AKRO $73.56
- AVG Volume (30 Days)
- KTB 566.8K
- AKRO 1.7M
- Earning Date
- KTB 11-03-2025
- AKRO 11-07-2025
- Dividend Yield
- KTB 3.03%
- AKRO N/A
- EPS Growth
- KTB N/A
- AKRO N/A
- EPS
- KTB 3.88
- AKRO N/A
- Revenue
- KTB $2,833,659,000.00
- AKRO N/A
- Revenue This Year
- KTB $20.49
- AKRO N/A
- Revenue Next Year
- KTB $11.27
- AKRO N/A
- P/E Ratio
- KTB $18.03
- AKRO N/A
- Revenue Growth
- KTB 9.91
- AKRO N/A
- 52 Week Low
- KTB $50.00
- AKRO $21.34
- 52 Week High
- KTB $96.80
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- KTB 34.75
- AKRO 69.26
- Support Level
- KTB $71.02
- AKRO $54.10
- Resistance Level
- KTB $74.17
- AKRO $54.37
- Average True Range (ATR)
- KTB 2.71
- AKRO 0.18
- MACD
- KTB -0.75
- AKRO -0.22
- Stochastic Oscillator
- KTB 7.57
- AKRO 95.00
About KTB Kontoor Brands Inc.
Kontoor Brands Inc is a lifestyle apparel company. It is engaged in designing, manufacturing, sourcing, marketing, and distribution of its portfolio of brands, including Wrangler and Lee. It manufactures its products in owned and leased facilities and distributes the products through both brick-and-mortar and e-commerce retailers. The Company has two reportable segments: Wrangler and Lee. It generates the majority of its revenue from the Wrangler segment. The company's geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.